Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 8/20 | 0.68 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.63 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.63 |
| ▸ | TBXAS1 | P24557 | 5/20 | 0.61 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.60 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4701021 | 0.85 | CYP19A1 (0.70) | CYP19A1CYP11B1CYP11B2TBXAS1CYP2A6 | |
| SCHEMBL4492287 | 0.85 | CYP19A1 (0.75) | CYP19A1CYP11B1CYP11B2TBXAS1CYP2A6 | |
| SCHEMBL6308819 | 0.84 | TBXAS1 (0.65) | CYP19A1TBXAS1KMT2A | |
| SCHEMBL31481149 | 0.84 | TBXAS1 (0.64) | CYP19A1CYP11B1CYP11B2TBXAS1CYP2A6 | |
| Hydrochloric Acid SCHEMBL9853939 | 0.84 | CYP19A1 (0.73) | CYP19A1CYP11B1CYP11B2TBXAS1CYP1A2 | |
| SCHEMBL12639833 | 0.84 | CYP19A1 (0.68) | CYP19A1CYP11B1CYP11B2TBXAS1CYP2A6 | |
| SCHEMBL1024261 | 0.82 | CYP11B1 (0.84) | CYP19A1CYP11B1CYP11B2TBXAS1CYP2A6 | |
| SCHEMBL773135 | 0.81 | CYP11B1 (0.59) | CYP19A1CYP11B1CYP11B2TBXAS1CYP2A6 | |
| SCHEMBL773136 | 0.81 | CYP11B1 (0.59) | CYP19A1CYP11B1CYP11B2TBXAS1CYP2A6 | |
| SCHEMBL2926364 | 0.81 | CYP19A1 (0.78) | CYP19A1CYP11B1CYP11B2TBXAS1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12344623-B2 | Thiazolopyridine derivatives as adenosine receptor antagonists | DOMAIN THERAPEUTICS SA (FR) | 2025-07-01 | — | — | US | claimed |
| US-20220119412-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-04-21 | — | — | US | claimed |
| US-20040110778-A1 | Heterocyclic compounds as ligands of the GABAA receptor | YOHANNES DANIEL (US) | 2004-06-10 | — | — | US | claimed |
| US-20030105081-A1 | Heterocyclic compounds as ligands of the GABAA receptor | PFIZER INC | 2003-06-05 | — | — | US | claimed |
| US-12344623-B2 | Thiazolopyridine derivatives as adenosine receptor antagonists | DOMAIN THERAPEUTICS SA (FR) | 2025-07-01 | — | — | US | disclosed |
| US-20220119412-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-04-21 | — | — | US | disclosed |
| US-6949562-B2 | Heterocyclic compounds as ligands of the GABAA receptor | NEUROGEN CORPORATION (US) | 2005-09-27 | — | — | US | disclosed |
| US-6653471-B2 | Tricyclic heteroaromatic compounds containing pyrrole ring; central nervous system disorder treatment; side effect reduction | NEUROGEN CORPORATION | 2003-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105081-A1 | Heterocyclic compounds as ligands of the GABAA receptor | GABRB1, GABRP, GABRA1 | CYP19A1 543/4885CYP11B1 328/4885CYP11B2 336/4885 |
| US-12344623-B2 | Thiazolopyridine derivatives as adenosine receptor antagonists | ADORA1, ADORA2A, ADORA3 | CYP19A1 3132/4885CYP11B1 1256/4885CYP11B2 1074/4885 |
| US-20040110778-A1 | Heterocyclic compounds as ligands of the GABAA receptor | GABRB1, GABRP, GABRA1 | CYP19A1 543/4885CYP11B1 328/4885CYP11B2 336/4885 |
| US-20220119412-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA1, ADORA2A, ADORA3 | CYP19A1 3132/4885CYP11B1 1256/4885CYP11B2 1074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.